Update on recommendations for assessing response from the Third International Workshop on Waldenström's macroglobulinemia

Eva Kimby, Steven P. Treon, Athanasios Anagnostopoulos, Meletios Dimopoulos, Ramon Garcia-Sanz, Morie A. Gertz, Stephen Johnson, Veronique LeBlond, Jean Paul Fermand, David G. Maloney, Giampaolo Merlini, Pierre Morel, Enrica Morra, Gwen Nichols, Enrique M. Ocio, Roger Owen, Marvin Stone, Joan Bladé

Research output: Contribution to journalArticle

91 Scopus citations

Abstract

This report by an international consensus panel updates current recommendations for defining clinical response in Waldenström's macroglobulinemia (WM). The previously published response criteria incorporated parameters for monoclonal protein reduction and/or improvement of marrow and nodal involvement, and included definitions of complete and partial remissions. The criteria have been updated to include minor response and stable disease categories. In addition, the criteria now recognize that delayed responses after treatment with nucleoside analogues and biologic agents and the time point for assessing response in patients with WM should be considered so as to not miss or miscategorize a response. The new criteria should therefore help in better delineating responses to therapy in patients with WM, particularly with the wide use of nucleoside analogues and biologically based agents for this disease.

Original languageEnglish (US)
Pages (from-to)380-383
Number of pages4
JournalClinical Lymphoma and Myeloma
Volume6
Issue number5
DOIs
StatePublished - Mar 2006

    Fingerprint

Keywords

  • Bence Jones protein
  • Disease progression
  • Immunoglobulin M
  • Relapse

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Kimby, E., Treon, S. P., Anagnostopoulos, A., Dimopoulos, M., Garcia-Sanz, R., Gertz, M. A., Johnson, S., LeBlond, V., Fermand, J. P., Maloney, D. G., Merlini, G., Morel, P., Morra, E., Nichols, G., Ocio, E. M., Owen, R., Stone, M., & Bladé, J. (2006). Update on recommendations for assessing response from the Third International Workshop on Waldenström's macroglobulinemia. Clinical Lymphoma and Myeloma, 6(5), 380-383. https://doi.org/10.3816/CLM.2006.n.013